Institution Directory

Clinical trials at Massachusetts General Hospital

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1469

Shown on this page

Current sort

Stored official records

Conditions: Consciousness Disorders, Disorders of Consciousness Due to Severe Brain Injury
Interventions: The Brainsonix BX Pulsar 1002 was designed to deliver low-intensity focused ultrasound pulsations (LIFUP) to the human brain.; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years to 79 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: Los Angeles, California • Pomona, California • Boston, Massachusetts + 1 more

Conditions: HIV Infection, Menopause
Interventions: Micronized Progesterone, Placebo for estradiol gel, Placebo for micronized progesterone, Transdermal estradiol gel; Drug
Lead sponsor: Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections; Network
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 23
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more

Conditions: Asthma
Interventions: ICS/LABA, Matching Placebo, dupilumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 12 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 51
States / cities: Bakersfield, California • La Jolla, California • Lancaster, California + 47 more

Conditions: Chronic Subdural Hematoma
Interventions: Conventional Surgery, Middle Meningeal Artery Embolization (MMAE); Procedure · Device
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 40 Years to 90 Years
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 31
States / cities: Phoenix, Arizona • Jacksonville, Florida • Miami, Florida + 26 more

Conditions: Advanced Solid Tumor, Bladder Cancer, Cervical Cancer, Esophageal Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Solid Tumor, Non-small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Recurrent Solid Tumor, Renal Pelvis Cancer, Triple Negative Breast Cancer, Urinary Bladder Neoplasm
Interventions: LY4101174; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 490 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 9
States / cities: Orlando, Florida • Atlanta, Georgia • Boston, Massachusetts + 5 more

Conditions: Radiation Oncology
Interventions: Radiation Treatment Plan Evaluation Learning Tool; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Bladder Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8
Interventions: Biopsy of Bladder, Biospecimen Collection, Cisplatin, Computed Tomography, Cystoscopy, Durvalumab, Fluorouracil, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Mitomycin, Patient Observation, Radiation Therapy; Procedure · Drug · Biological + 2 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 216
States / cities: Anchorage, Alaska • Fort Smith, Arkansas • Hot Springs, Arkansas + 153 more

Conditions: AML Arising After Exposure to Genotoxic Injury, AML Arising From Antecedent Hematologic Disorder (AHD), AML Arising From Myelodysplastic Syndrome (MDS), Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML
Interventions: AG-120, AG-221, cytarabine, daunorubicin, etoposide, idarubicin, mitoxantrone; Drug
Lead sponsor: Institut de Recherches Internationales Servier; Other
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 14
States / cities: Duarte, California • Los Angeles, California • Aurora, Colorado + 10 more

Conditions: Intracerebral Haemorrhage, Ischemic Stroke, Stroke, TIA (Transient Ischemic Attack)
Interventions: Savvy Medication Adherence Intervention; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 99 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Menopause-related Hot Flashes
Interventions: elinzanetant - reference formulation, placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 40 Years to 65 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Hypoxemic Respiratory Failure, Nitric Oxide, Obesity, Respiratory Insufficiency
Interventions: Nitric oxide; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Adult T-cell Leukemia/Lymphoma, Aggressive NK-cell Leukemia, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-negative, Angioimmunoblastic T-cell Lymphoma, Breast Implant-Associated Anaplastic Large Cell Lymphoma, Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form, Chronic Lymphoproliferative Disorder of NK Cells, Enteropathy-associated T-cell Lymphoma, Extranodal NK/T-cell Lymphoma, Nasal Type, Follicular T-Cell Lymphoma, Hepatosplenic T-cell Lymphoma, Hydroa Vacciniforme-Like Lymphoproliferative Disorder, Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract, Intestinal T-Cell Lymphoma, Not Otherwise Specified, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Mycosis Fungoides, NK-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma, Primary Cutaneous Anaplastic Large Cell Lymphoma, Primary Cutaneous CD8-Positive Aggressive Epidermotropic T-Cell Lymphoma, Primary Cutaneous T-cell Lymphoma, Sezary Syndrome, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Systemic Epstein Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood, Systemic Epstein-Barr Virus Positive T-Cell Lymphoproliferative Disease of Childhood (Disorder), T-cell Large Granular Lymphocytic Leukemia, T-cell Lymphoma, T-cell Prolymphocytic Leukemia
Interventions: Optional Blood Sample and Nail Sample; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Not listed
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 26
States / cities: Duarte, California • San Diego, California • San Francisco, California + 20 more

About this Massachusetts General Hospital institution page

What this page lists: ClinicalTrials.gov records that list Massachusetts General Hospital in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Massachusetts General Hospital

Filter and sort this campus

Stored official records

Ultrasound Stimulation for Patients in a Disorder of Consciousness

Menopausal HT for Women Living With HIV (HoT)

Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma

Chronic Subdural Hematoma Treatment With Embolization Versus Surgery Study

A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors

Radiation Treatment Plan Evaluation Learning Tool Pilot Project

A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

Testing the Effectiveness of a Novel Intervention to Improve Medication Adherence in Stroke Survivors

Finding Links Between Hot flASHes and CardioVascular Disease

Inhaled Nitric Oxide in Severe Obesity

A Registry for People With T-cell Lymphoma

About this Massachusetts General Hospital institution page